Patent SG-11201807725W-A (SG)
Title: Methods of diagnosing cancer
Inventor: HAN WEIPING
IPC: A23L33/175
Filed: 2017-03-08
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111101110011111111111111101111011111 International Bureau ... ..... ..)d (10) International Publication Number ..... ......!::, (43) International Publication Date WO 2017/155467 Al 14 September 2017 (14.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/216 (2006.01) GO1N 33/574 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 35/00 (2006.01) C12Q 1/32 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A23L 33/175 (2016.01) A61P 3/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, G01N 33/68 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/SG2017/050112 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 8 March 2017 (08.03.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 10201601791W 8 March 2016 (08.03.2016) SG GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Connexis North Tower, Singapore 138632 (SG). (72) Inventors: HAN, Weiping; Consortium (SBIC), Biomedical LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, c/o Singapore Bioimaging GW, KM, ML, MR, NE, SN, TD, TG). Sciences Institutes, 11 Bi- opolis Way, #02-02 Helios, Singapore 138667 (SG). ER- Declarations under Rule 4.17: Bioimaging Consorti- ICKSEN, Russell E.; c/o Singapore - of inventorship (Rule 4.17(N)) Institutes, 11 Biopolis um (SBIC), Biomedical Sciences 138667 (SG). Published: Way, #02-02 Helios, Singapore (ASIA) PTE LTD; — with international search report (Art. 21(3)) (74) Agent: SPRUSON & FERGUSON P.O. Box 1531, Robinson Road Post Office, Singapore with sequence listing part of description (Rule 5.2(a)) 903031 (SG). CANCER (54) Title: METHODS OF DIAGNOSING NoQtumor ECG 2.0- TUMOT BCA.AS 2-0 - os ... t LFD m — .$ 4o L HFO+BC.kA 1-1 .4 IN Figure 4 ii- ir) ir) (57) : Disclosed are two methods of treating or preventing a proliferative disease as characterized and/or diagnosed by at Il ----. least one selected from an accumulation of branched-chain amino acid (s) (BCAA), suppression of activity or transcripts level of N BCAA catabolic enzyme(s) and a decrease in acylcarnitine level (C5:1 ), one comprising the administration of a BCAA catabolism C enhancer and/or branched chain alpha-ketoacid dehydrogenase complex (BCKDC) kinase inhibitor and the other comprising admin - el istration of a meal replacement with low BCAA levels. In three separate embodiments, methods of diagnosis or prognosis are dis - O closed, each comprising the measurement of the levels of a different marker, i.e. BCAA, BCAA catabolic enzymes or acylcarnitine (C5:1 ). In preferred embodiments, the proliferative disease is cancer. Also disclosed is a kit or microarray chip useful for methods 5- thereof.